A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal Alzheimer's Disease. Revised Protocol 10 incorporating Protocol Amendment 16 + Pharmacogenetics Blood Sample Amendment 01 - Site Specific (v2.0, dated 03-Mar-2009)

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal Alzheimer's Disease. Revised Protocol 10 incorporating Protocol Amendment 16 + Pharmacogenetics Blood Sample Amendment 01 - Site Specific (v2.0, dated 03-Mar-2009)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2015

At a glance

  • Drugs Avagacestat (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Sep 2015 Results published in the JAMA Neurology.
    • 14 Jul 2013 Results presented at the 2013 Alzheimer's Association International Conference .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top